Sahir
Jaggi.

Sahir Jaggi runs a startup that spent much of its early life pretending not to exist. Until May 2026 the company was called Tandem, it lived in what the venture business calls stealth, and it did what most people would agree is one of the least glamorous jobs in American medicine: sit between the doctor who prescribes a drug and the insurance company that decides whether the doctor is allowed to, and do the paperwork.

Then, in the space of a week, Tandem became Forus, disclosed a $160 million round from Thrive Capital, General Catalyst, and Accel, and admitted it had crossed a billion-dollar valuation. The company also admitted, more quietly, that its coverage map now includes every state in the country and nearly 80 percent of American zip codes, and that five of the ten largest global biopharma companies had signed on as customers. It is, in other words, no longer stealth.

Forus is offered free to doctors and free to patients. That leaves biopharma and, indirectly, the payer economy to fund the rest, which is a not-uninteresting business model in a sector where most software vendors are trying to charge the person who is already doing the paperwork.

What Forus actually does, in the language of its own product page, is prior authorization, appeals, enrollment forms, pharmacy routing, benefit verifications, specialty pharmacy coordination, PA renewal tracking, affordability programs, and patient communication. It integrates with every major cloud EHR. It is SOC 2 Type 2 certified. It is, per Jaggi's own account on the TBPN podcast in May, home to what he calls some of the best fax AI in existence, because in American healthcare fax is still, incredibly, the standard.

Jaggi studied biomedical engineering and computer science at Columbia. He was, at nineteen, working in the Sia Lab; Columbia Engineering Magazine wrote him up in Fall 2014 as one of those undergraduates who had already begun collecting the résumé line items that founders tend to accumulate before anyone knows they will be founders. Rough Draft Ventures, Blue Apron, an eventual arrival at Oscar Health.

At Oscar he stayed for something like six years, running product for care delivery and patient experience and later serving as Director of Product Strategy. Oscar is a health insurance company. Which means Jaggi spent six years reading, in effect, complaint tickets: the taxonomy of the ways American prescription drug coverage falls over.

A great many prescriptions, it turns out, are written and never filled. A great many others require a form called a prior authorization, which is a document by which an insurance company asks a doctor to explain, in writing, why the doctor believes the doctor is right. Prior authorizations are frequently sent by fax. Fax is HIPAA-compliant and, for reasons that go back to the 1990s, will not die.

In 2023 Jaggi left Oscar and started Tandem with a $7 million seed round from General Catalyst and Thrive Capital - the same firms that would lead the Series B three years later. In 2025 Forbes put him on the 30 Under 30 healthcare list. In 2026 he renamed the company.